Pieris Pharmaceuticals Inc

NASDAQ:PIRSUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Pieris Pharmaceuticals, Inc. is a biotechnology company, which discovers and develops Anticalin-based drugs to target validated disease pathways. The Company’s clinical pipeline consists of immuno-oncology (IO), bispecific in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Its Anticalin platform technology focuses on low molecular-weight Anticalin proteins that can bind tightly and specifically to a diverse range of targets. The Anticalin technology is modular, which allows it to design multimeric Anticalin based bi- and multi- specific proteins to bind with specificity to two or more targets at the same time. S095012 consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins genetically fused to each arm of the C-terminal heavy chain of the antibody.

Contact Information

Headquarters

225 Franklin Street, 26Th FloorBOSTON, MA, United States 02110

Phone

857-246-8998

Fax

---

Executives

Independent Director

James Geraghty

President, Chief Executive Officer, Director

Stephen Yoder

Chief Financial Officer, Senior Vice President

Thomas Bures

Senior Vice President, Chief Scientific Officer

Hitto Kaufmann

Senior Vice President, Chief Development Officer

Shane Olwill